Post Type Archives: News

Bracco Imaging, a global pharmaceutical company that develops, manufactures, and markets innovative healthcare solutions, today announced its first expansion into the cell therapy space, driven by its expertise and newly developed applications of its long-established microbubble technology. Bracco’s new lipid-based microbubble product is designed to simplify key upstream steps in cell therapy manufacturing, offering a […]

Ardena, a specialist CDMO and bioanalytical CRO enabling precision medicines and other complex therapies, today announced that it has completed the divestment of its drug substance (API) site in Södertälje, Sweden, to Nanologica AB. The business will operate as a wholly owned subsidiary within the Nanologica Group and will revert to its original name, Syntagon […]

DFE Pharma, a global leader in pharmaceutical excipients, has launched EcoLact® 2030, a pioneer initiative within the industry, designed to bring transparency and verified sustainability to its current lactose offering. EcoLact® 2030 provides pharmaceutical manufacturers access to auditable CO₂ data and full value-chain traceability, enabling them to demonstrate Scope 3 emission reductions without operational disruption. […]

Pharmapack 2026, Europe’s leading event for pharmaceutical packaging and drug delivery, this year welcomed a record number of visitors, exhibitors, and speakers to Paris Expo, Porte de Versailles for two days of networking, showcasing innovation, and speaker sessions. Over 6,600 attendees visited the event, which hosted 430+ exhibiting companies and delivered 80 sessions covering hot […]

WuXi Biologics and Sinorda Biomedicine, a biomedical company advancing treatments in the fields of tract diseases, tumor immunity, and autoimmune diseases, announced a strategic collaboration concerning Sinorda’s therapeutic candidate SND006 on January 29th, 2026. According to a company press release announcing the agreement, WuXi will provide clinical supply for SND006’s preclinical pharmacology studies. SND006 is […]

SanegeneBio, a clinical-stage biotechnology company developing RNAi therapeutics, and Genentech, a member of the Roche Group, announced a global licensing agreement on February 2nd, 2026. In a deal valued at over $1.5 billion, Genentech will receive exclusive worldwide rights to develop and commercialize an undisclosed program based on SanegeneBio’s proprietary RNAi platform. According to a […]

Immuto Scientific, a biotechnology company advancing novel structural approaches to therapeutic target discovery, announced a target discovery agreement with the University of Wisconsin-Madison (UW-Madison) on January 29th, 2026. Led by Dr. Dustin Deming, Professor of Medicine at UW-Madison, the parties will collaborate in a multi-year research project aimed at discovering disease-specific surface protein conformations (SPCs), […]

Ipsen and Origami Therapeutics, a biotech company developing small-molecule protein degraders and conformation correctors, announced a global collaboration and option agreement on January 30th, 2026. According to a company press release, the goal of the collaboration is to develop a small-molecule protein degrader program targeting a rare, inherited neurodegenerative disorder. According to the release, Ipsen […]

AstraZeneca announced plans to invest $15 billion in its Chinese facilities to expand its manufacturing and R&D capabilities on January 28th, 2026. This investment, which is set to last through 2030, will be used to enhance the company’s cell therapy and radioconjugate capabilities, and will span from drug discovery to manufacturing. According to a company […]

Tenpoint Therapeutics, a biotechnology company developing treatments for impaired vision, announced FDA approval of Yuvezzi as a treatment for presbyopia on January 28th, 2026. The treatment, a prescription eye drop, is indicated for adults experiencing blurry close-up vision due to age. Tenpoint expects the treatment to be commercially available in Q2 2026. Yuvezzi is a […]